Three-step one-way model in terahertz biomedical detection

Yan Peng¹, Jieli Huang², Jie Luo¹, Zhangfan Yang¹, Liping Wang¹, Xu Wu¹, Chen Yu², Qing Hu², Min Gu¹, Xicheng Zhang³, Yiming Zhu¹,*, Songlin Zhuang¹

¹Terahertz Technology Innovation Research Institute, Shanghai Key Lab of Modern Optical System, and Shanghai Cooperation Innovation Centre of Terahertz Spectroscopy and Imaging Technology, University of Shanghai for Science and Technology, Shanghai 200093, P. R. China.
²Department of Nephrology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
³Department of Electrical Engineering and Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.
⁴Laboratory of Artificial-Intelligence Nanophotonics, University of Shanghai for Science and Technology, Shanghai 200093, P. R. China.
⁵The Institute of Optics, University of Rochester, Rochester, New York 14627, USA.

*The first coauthor.

Corresponding author: *ymzhu@usst.edu.cn, †yuchen@tongji.edu.cn

Abstract

Terahertz technology has broad application prospects in biomedical detection. However, the mixed characteristics of actual samples make the terahertz spectrum complex and difficult to distinguish, and there is no practical terahertz detection method for medical clinics. Here, we propose a three-step one-way terahertz model, presenting a detailed flow analysis of terahertz technology in the biomedical detection of renal fibrosis as an example: 1) **biomarker determination**: screening disease biomarkers and establishing the terahertz spectrum and concentration gradient; 2) **mixture interference removal**: clearing the interfering signals in the mixture for the biomarker in the animal model and evaluating and retaining the effective characteristic peaks; and 3) **individual difference removal**: excluding individual interference differences and confirming the final effective terahertz parameters in the human sample. The root mean square error of our model is three orders of magnitude lower than that of the gold standard, with profound implications for the rapid, accurate and early detection of diseases.

Keywords
Terahertz spectroscopy, renal fibrosis, biomedical detection, biomarker, mixture interference, individual difference.

**Introduction**

The early detection, early diagnosis and early treatment of diseases directly affect the quality of life and survival rate of patients. Pathological diagnosis is the gold standard for the diagnosis of many diseases. The corresponding technologies include light microscopic morphological detection, immunohistochemical enzyme labelling, fluorescence in situ hybridization and gene rearrangement detection [1-5]. Light microscopic morphological detection can judge the nature of the disease by observing the morphological changes in cells but is subjective because this approach is influenced by the observer's experience and intuition. Immunohistochemical enzyme labelling and fluorescence in situ hybridization (FISH) both use the fluorescent labelling of specific proteins or nucleic acids for localization and quantitative labelling, and gene rearrangement detection technology is used to detect and diagnose diseases by gene sequencing of lesion tissue. However, the sample processing of these techniques is cumbersome and time-consuming and requires large amounts of reagents and dyes, so the samples cannot be reused, and the judgement of results also has subjective interference. Other spectroscopic methods, such as fluorescence spectroscopy and Raman spectroscopy, can also be used for sample detection. Fluorescence spectrometry mainly uses certain fluorescent dyes to form complexes with substances that do not ordinarily emit fluorescence but are induced to emit fluorescence before determination [6-9]. The procedure is complicated, the fluorescence intensity is affected by the wavelength and temperature of the stimulated luminescence, and the data stability is poor. Raman spectroscopy exposes the sample to a strong laser and collects the scattering signal for material identification [10, 11]. However, the high-power laser easily damages the samples, which is not conducive to secondary detection, and the detection error at low concentrations is large,
so the method cannot be applied to the early quantitative analysis of diseases. Therefore, there is an urgent need for rapid, label-free, simply operated, low-sample-loss, and low-cost detection technology for the early diagnosis of diseases.

Terahertz (THz) waves (0.1–10 THz) lie between the millimetre wave and infrared band, which is of significant importance to the biological sciences due to providing information complementary to traditional spectroscopic measurements of low-frequency bond vibrations, hydrogen bond stretching, and bond torsions in liquids and gases [12]. Therefore, the collective behaviour (vibration and rotation) characteristics of biomolecules make THz spectroscopy a promising sensing modality for clinical diagnosis [13]. Because of these properties and its non-destructiveness, accuracy, rapidity and good penetrability [14], THz spectroscopy also has many other potential applications in several research fields, including physics [15, 16], biology [17-21], chemistry [22, 23], and medicine [24, 25]. At present, substance identification with THz technology is mainly based on the fingerprint peaks of compounds. Some studies have indicated that the approach can be combined with chips, algorithms, reagents and other auxiliary means to improve the recognition accuracy [18, 26-30]. However, THz technology has not been effectively applied in actual medical diagnosis or evaluation, because human tissue is a mixture of many substances, and the THz fingerprint spectra of these substances overlap with each other, which interferes with the quantitative analysis of disease markers or key substances. More importantly, there are individual differences between human bodies, and the proportions of various components are continually changing, which leads to a rapid decrease in the effectiveness of auxiliary means such as algorithms. To date, the application of THz technology to biomedical sample detection is still in the process of exploration, and there is no standardized process or model to assist the accurate diagnosis of diseases.
In this paper, we propose a three-step one-way THz model to analyse the application steps and processes of using THz spectroscopy to detect real diseases. We hope that we can apply this model to improve the application of THz technology in research on related diseases and to realize the rapid and effective detection of pathological specimens of various diseases by using THz technology.

The THz three-step one-way model is divided into three steps, namely, biomarker determination, mixture interference removal, and individual difference removal. In the first step, we need to screen and determine the biomarkers or key substances (of which there can be multiple), test the THz fingerprint spectrum, and establish the gradient relationship between the biomarker concentration and THz parameters to lay the foundation for subsequent calibration of the disease pathological stage. Second, to verify the possibility of applying THz technology to recognize biomarkers in biological tissues (mixtures), we initially used animal models to predict and quantify these markers in accordance with scientific research ethics. It is possible to analyse whether the biomarkers of rat pathological samples can be identified by observing the pathological samples of rats. The third step is mainly to determine whether the individual differences in the human body will affect the qualitative identification and quantitative analysis of the biomarkers by THz spectroscopy and to verify the validity and accuracy of the biomarker parameters. The above three steps can be implemented only in one direction; otherwise, it is easy to reach a misdiagnosis or incorrect stage identification due to individual differences or mixture identification errors.

To assess the feasibility of the THz three-step one-way model, we used renal fibrosis, a common chronic disease, as an example. Renal fibrosis is a common pathological manifestation of end-stage renal disease; its main pathological features are glomerulosclerosis, tubular atrophy and increased extracellular matrix deposition [31]. Studies have shown that the assessment of renal fibrosis can guide the treatment and prognosis of autologous kidneys [32] and transplanted kidneys [33]. There are three methods for the diagnosis of fibrosis: histological evaluation, imaging
evaluation and biomarker detection. 1) Histology is the gold standard for the diagnosis of fibrosis and can directly observe the degree of fibrosis, but its identification depends on the subjective judgement of pathologists, and there are individual differences. In addition, in some cases, there are sampling errors in the tissues obtained from core biopsy [34]. Moreover, there are time limitations in histopathological detection: sample preparation takes a long time (approximately 15 hours), preventing rapid determination of the degree of fibrosis. 2) Imaging evaluation methods, including ultrasound and functional magnetic resonance imaging (MRI), are new noninvasive techniques. Renal fibrosis is reflected by observing the renal elasticity, oxygen content and blood perfusion. However, the identification of renal fibrosis is easily affected by many factors, such as blood pressure, body weight, respiratory movement and differences in subjective judgement among observers, resulting in low detection accuracy [35]. 3) The use of biomarkers in haematuria as a noninvasive detection method is expected to be usable to monitor the progression of renal fibrosis [36]. However, some promising biomarkers, such as microRNAs [37], still suffer from instability or lack of regularity as the disease progresses. Therefore, we expect to solve these problems through the THz three-step one-way model.

Materials and Methods

Terahertz time-domain spectroscopy (THz-TDS)

The experimental setup used here is THz time-domain spectroscopy. In our experiments, we used an 800 nm femtosecond laser with a pulse duration of 100 fs, a repetition rate of 76 MHz, and an average power of 150 mW. The emitted laser beam was split into a pump beam and probe beam by a 50/50 beam splitter. A pump beam modulated by an optical chopper was focused on a gallium arsenide (GaAs) photoconductive emitter of THz waves. The diverging THz beam was collected and focused by four off-axis paraboloid mirrors to pass through samples, and then, the probe beam
was used to detect the THz wave by photoconductive antennas. For our experimental system, the effective bandwidth for the measured signals ranged from 0.2 to 2.0 THz, the spectrum resolution was \( \sim 15 \text{ GHz} \), and the signal-to-noise ratio (SNR) was greater than 1000:1. All the spectra were averaged 256 times to ensure a high SNR. The sample absorbance \( \alpha(\omega) \) was calculated by using the following equation: 
\[
\alpha(\omega) = \log \left( \frac{I_{\text{ref}}(\omega)}{I_{\text{sam}}(\omega)} \right)/d,
\]
where \( d=0.1 \text{ mm} \) is the thickness of the sample, \( I_{\text{sam}}(\omega) = E_{\text{sam}}(\omega) \times E_{\text{sam}}(\omega)^* \) is the power spectrum of the sample, and \( I_{\text{ref}}(\omega) = E_{\text{ref}}(\omega) \times E_{\text{ref}}(\omega)^* \) is the power spectrum of the reference signal.

**Preparation of pure L-hydroxyproline samples**

Pure L-hydroxyproline was purchased in powder form (Sigma-Aldrich) at the highest purity available (≥99%). The tablets were prepared with 30 mg of L-hydroxyproline and 120 mg of high-density polyethylene (powders, 40-48 μm particle size), which were then pressed into discs under a pressure of 4 tons. The thickness of the sample tablet was approximately 1 mm, and the diameter was 13 mm. The entire THz spectroscopy system was enclosed in a sealed box filled with dry air (humidity<2%) to reduce water vapour absorption.

**Variable-temperature liquid nitrogen cryostat**

A variable-temperature liquid nitrogen cryostat (Optistat DN2, Oxford Instruments) equipped with high-density polyethylene windows is a commercial product designed for optical spectroscopy. The cryostat temperature can continuously vary between 77 K and 500 K, with an accuracy of ±0.5 K. In our experiments, the cryostat was placed at the THz radiation focal point between the off-axis parabolic mirrors of the THz-TDS system. The sample was placed inside in the cryostat, and THz radiation was passed through the sample to obtain the fingerprint spectrum.

**Preparation of animal model samples**
Male Sprague-Dawley (SD) rats aged 8-12 weeks with body weights of 180-200 g were provided by the Jiesijie Animal Experimental Center (Shanghai, China). All rats were nurtured and maintained according to the ‘Care and Use of Laboratory Animals’ guidelines published by the National Institute of Health. The Experimental Animal Ethics Committee of Shanghai Tongji Hospital (Shanghai, China, document No. 2020-DW-002) approved the research protocol. A total of 20 male SD rats were randomly divided into the following four groups: the sham surgery group (sham, n=5), the UUO d3 group (d3, n=5), the UUO d5 group (d5, n=5), the UUO d7 group (d7, n=5), and the UUO d14 group (d14, n=5). After anaesthesia by using 3% intraperitoneal pentobarbital (2 ml/kg), the UUO groups received left ureteral ligation in the sham group, and the left ureter was separated, but not ligated. On days 3, 7, and 14 after surgery, the rats were sacrificed using euthanasia. Their left kidneys were removed and homogenized and then placed into sterile tubes that were labelled. All sterile tubes were kept in a 200 K freezer. Then, rat left kidney homogenates were carefully mounted between two flat quartz plates with a groove thickness of 480 μm.

**Masson staining**

After the kidneys were harvested, they were sliced axially into 3-mm-thick sections, fixed in 10% buffered formalin, embedded in paraffin, and deparaffinized by submerging the slides in 4 changes of xylene for 2 minutes each, then dehydrated in 2 changes of absolute alcohol for 2 minutes, 1 change of 95% alcohol for 2 minutes, and 1 change of 70% alcohol for 2 minutes. The slides were then mordanted by submersion in Bouin’s fixative for 1 hour at 50-60°C, washed in gently running tap water until the yellow colour completely disappeared, rinsed in distilled 3 times, stained by submersion in Weigert’s iron haematoxylin for 10 minutes, rinsed in warm tap water for 15 minutes, stained by submersion in Biebrich scarlet-acid fuchs in for 15 minutes, immersed in phosphomolybdic-phosphotungstic acid for 15 minutes, and immersed in Aniline blue solution for
15 minutes. Next, the slides were rinsed with distilled water 3 times, immersed in 1% acetic water for 1 to 3 minutes, rinsed in distilled water 3 times, dehydrated by submersion in 4 absolute alcohol changes for 2 minutes each, and cleared by submersion in 4 xylene changes for 2 minutes each. Finally, the coverslip was mounted in resinous mounting media.

**Preparation of human kidney samples**

Fourteen human kidney samples were obtained from Tongji Hospital. The processing method of human kidneys was the same as that of rat kidneys. The trial was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. The ethics committees of Tongji Hospital (Shanghai, China, document No. K-W-2021-001) approved the research protocol. All patients provided written informed consent before entering the trial.

**Alkaline hydrolysis (AH)**

First, kidney tissue (40 mg wet weight) was sufficiently mixed with the digest (1 mL). After the test tube was covered by a stopper, the mixture was heated at 96°C for 20 minutes, and the pH was adjusted to 6.0. Second, distilled water was added to the test tube until the total volume reached 10 mL. Next, diluted lysate (4 mL) and quantum active carbon (30 mg) were added to the test tube and mixed sufficiently. The mixture was then centrifuged at 3500 rpm for 10 minutes. The supernatant (1 mL) was transferred into a clean tube. The remainder of the experimental process is described in Table 1.

**Table 1.** Experimental process of alkaline hydrolysis (AH).

|                      | Blank tube | Standard tube | Sample tube |
|----------------------|------------|---------------|-------------|
| Distilled water (mL) | 1.0        |               |             |
| 5 µg/mL standard working solution (mL) | 1.0        |               |             |
| Supernatant          |            |               | 1.0         |
|                 | 0.5 | 0.5 | 0.5 |
|----------------|-----|-----|-----|
| Dichloramine-T |     |     |     |
| Mix sufficiently and let stand for 10 minutes. |
| Perchloric acid | 0.5 | 0.5 | 0.5 |
| Mix sufficiently and let stand for 10 minutes. |
| Dimethylaminobenzaldehyde | 0.5 | 0.5 | 0.5 |

The reagents were mixed well, and the mixture was placed in a 60°C water bath for 15 minutes, cooled to room temperature, and centrifuged at 3500 rpm for 10 minutes. The supernatant was taken and transferred into the spectrometer (at 550 nm) to measure the absorption (OD values) of all tubes (distilled water was used as a blank).

Finally, the content of L-hydroxyproline can be calculated according to the following formula:

$$\text{Hydroxyproline content (} \mu\text{g/mL)} = \frac{\text{OD}_{\text{Standard}} - \text{OD}_{\text{Blank}}}{\text{OD}_{\text{Standard}} - \text{OD}_{\text{Blank}}} \times \text{Standard content (5 } \mu\text{g/mL)} \times \frac{\text{Total volume of lysate (10 mL)}}{\text{Tissue wet weight (mg)}}$$

**Liquid chromatography-mass spectrometry (LC-MS)**

Kidney tissue (10 mg) was cut into slices and then transferred into a screw vial containing 6 mol/L HCl (1 mL). After the vial cap was screwed on tightly, the mixture was heated for 6 hours at 110°C. The hydrolysed mixture was then centrifuged at 12000 rpm for 10 minutes at 4°C. The supernatant (100 μL) was transferred into a clean Eppendorf tube containing 10 μL of internal standard (10 μg/mL proline-13C in water) and acetonitrile (ACN, 480 μL). After being mixed on a vortexer at 1400 rpm for 5 minutes, the mixture was centrifuged at 12000 rpm for 5 minutes at 4°C. The supernatant (100 μL) was transferred into an Ultrafree centrifugal filter. After centrifugation at 12000 rpm for 5 minutes at 4°C, the filtrate (50 μL) was transferred into a 150 μL insert fixed in a 2 mL vial for analysis.
The prepared sample was separated on an Agilent 1260 Infinity liquid chromatography instrument equipped with a 2.1 × 100 mm Venusil ASB-C18 3.0 μm column (Agela Technologies, Tianjin, China) held at 25°C. The solvent system consisted of water/ACN/formic acid (v/v, 949/50/3, solvent A) and methanol/formic acid (v/v, 998/2; solvent B). The gradient program started at 99% solvent A for 2.5 minutes, which was decreased linearly to 83% solvent A in 1.5 minutes, then decreased linearly to 5% solvent A in 1 minute and maintained for 5 minutes, returned linearly to 99% solvent A in the following 0.5 minutes, and finally equilibrated for 2.0 minutes until the next analysis. The flow rate was 0.3 mL/min. The injection volume was 5 µL, and the samples were kept at 10°C in the autosampler. Analytes were monitored by positive mode electrospray ionization tandem mass spectrometry in MRM mode on an AB Sciex QTrap6500 Mass Spectrometer (AB Sciex, Framingham, MA). By direct infusion of the single-compound solution at a concentration of 1 µM, the declustering potential (DP), collision energy (CE), and collision cell exit potential (CXP) for each analyte and internal standard were optimized for the acquisition of the maximum intensity of the precursor and production ions, respectively. The precursor and dominant daughter ions used to set up the transition monitored in MRM mode are presented in Table 2. The dwell time was set to 40 ms for each compound. The accuracy of the analyte ranged from 90~110%, with an RSD less than 10%.

Table 2. The MRM transitions and associated parameters for the analyte and internal standard.

| Compounds               | Precursor ion (m/z) | Daughter ion (m/z) | DP (V) | CE (V) | CXP (V) |
|-------------------------|---------------------|-------------------|--------|--------|---------|
| L-proline-1-13C         | 116.9               | 40.0              | 53.0   | 21.0   | 11.0    |
| hydroxyproline          | 132.0               | 67.9              | 22.0   | 26.8   | 10.1    |

Results

STEP 1: Biomarker determination
By analysing the biological process and characteristics of fibrosis, we know that collagen is the main component of the extracellular matrix. The accumulation of extracellular matrix in renal tissue increases with the progression of fibrosis, and the content of collagen, as its main component, also increases. However, collagen itself is a mixture of a variety of proteins and substances, so it is not suitable for use as a biomarker for THz technology. Regarding L-hydroxyproline, the main component of collagen, 1) its concentration is relatively fixed in mammalian collagen (approximately 14.4%), which provides reliability for stage evaluation; 2) its molecular weight is low (131.1), and it may have clear characteristic peaks in the THz band; and 3) it is stable and difficult to react with other substances. Therefore, L-hydroxyproline has the potential to be used to identify the concentration of collagen and the developmental stage of renal fibrosis, and it was chosen as the biomarker here.

Before the experimental measurements, we needed to confirm whether the absorption peaks of the biomarker were located within the spectral range of the THz time-domain spectroscopy (THz-TDS) system. *Ab initio* calculations based on density functional theory (DFT) were performed to study the vibrational and rotational modes as well as the intermolecular interactions. The BP86 functional and 6-31++G(d,p) basis set were applied. We employed a dimer model for the molecule, where the signal molecule structure of L-hydroxyproline was obtained from the ChemSpider website. Our DFT-based calculations and analyses were implemented in the Gaussian09 package [38].
**Fig. 1 Molecular simulation and THz spectrum of L-hydroxyproline.**

- **a** Molecular model of L-hydroxyproline.
- **b** DFT calculated results of L-hydroxyproline.
- **c** Absorption spectrum of pure L-hydroxyproline measured experimentally by THz-TDS at room temperature.
- **d** to **f** Several vibration modes corresponding to the absorption peaks of L-hydroxyproline. 0.76 THz, 1.17 THz, and 1.64 THz. White, grey, red, and blue balls represent H, C, O, and N atoms, respectively. Yellow arrows indicate the vibrational direction of the atom. Black dotted and red dashed boxes refer to the dominant functional groups in the vibration modes and the entire molecular vibration of the ring, respectively.
- **g** Spectrum of L-hydroxyproline changes with the detection temperature from 290 K to 80 K at 30 K intervals.
- **h** Frequency shift of L-hydroxyproline absorption peaks as a function of temperature.

**Table 3.** Calculated absorption peaks of L-hydroxyproline and vibration model analysis.

| Absorption peak | DFT results | Dominant vibration model |
|-----------------|-------------|--------------------------|
| 1               | 0.76 THz    | The vibration of the propyl alcohol group of the right pyrrolidine ring. Under the intermolecular hydrogen bond, the left molecule vibrates back and forth following the right molecule [see Fig. 1d]. |
The torsion and vibration of the right pyrrolidine ring. Under the intermolecular hydrogen bond, the up-and-down vibration of the left L-hydroxyproline molecule causes the absorption peak at 1.17 THz [see Fig. 1].

The combination of the right-left vibration of the right molecule and the strong contractions of the left molecule [see Fig. 1f].

After confirming that the absorption peaks were located within the THz spectral window, we measured the THz absorption spectrum of pure L-hydroxyproline. The corresponding experimental results are shown in Fig. 1c, revealing clear and distinctive absorption peaks at 0.73, 1.13, and 1.78 THz, which agree reasonably well with the DFT results. Additionally, considering that real tissue samples provided by the hospital will be frozen and that the characteristic peaks are dependent on the test temperature, we also tested pure L-hydroxyproline at different temperatures (290, 260, 230, 200, 170, 140, 110, and 80 K) by using a variable-temperature liquid nitrogen cryostat (see Methods). The corresponding results are shown in Fig. 1g. For convenience, all spectra are offset at a fixed interval. These peaks have different frequency shifts as the temperature increases: peak 3 presents the classical redshift, while peak 1 and peak 2 exhibit unusual blueshifts. For example, at 80 K, the absorption peaks are located at 0.64, 1.02, and 1.82 THz. To show this process more clearly, we plot the frequency shift of absorption peaks as a function of temperature in Fig. 1h. The corresponding frequency values are presented in Table 4.

Table 4. The frequency values (THz) of pure L-hydroxyproline absorption peaks at different temperatures.

| Temperature  | 80 K | 110 K | 140 K | 170 K | 200 K | 230 K | 260 K | 290 K |
|--------------|------|-------|-------|-------|-------|-------|-------|-------|
| Peak 1       | 0.44 | 0.49  | 0.53  | 0.59  | 0.64  | 0.67  | 0.70  | 0.72  |
| Peak 2       | 0.76 | 0.82  | 0.89  | 0.96  | 1.02  | 1.08  | 1.13  | 1.15  |
| Peak 3       | 1.86 | 1.85  | 1.84  | 1.83  | 1.82  | 1.81  | 1.80  | 1.79  |
Similar to the classical case, peak 3 undergoes a redshift as the temperature increases. This temperature dependence of the spectra can be explained by the anharmonicity of the vibrational potentials [39]. Interestingly, peak 1 and peak 2 show different behaviours, and they exhibit a blueshift as the temperature increases. Based on the DFT analysis, we deduce that the blueshift is due to competition between the intramolecular and intermolecular hydrogen bonds. As the temperature increases, thermal expansion of the intermolecular hydrogen bond partially restores the electron density of intramolecular hydrogen bonds [40], resulting in the intramolecular hydrogen bond being “harder” and its coefficient of stiffness being “stronger”. Because the potential curve of the hydrogen bond near the local minimum is described by the harmonic oscillator potential, the vibration frequency is proportional to the stiffness coefficient. Therefore, as the temperature increases, the vibration frequency tends to increase, and the two absorption peaks undergo a blueshift.

For subsequent analysis of the relationship between the THz characteristic information and the evolution stage of renal fibrosis, we tested the THz spectrum of L-hydroxyproline at different concentrations (see Methods). As shown in Fig. 2a, when the content of L-hydroxyproline was varied from 2.5 mg to 20 mg, the corresponding THz absorption peaks exhibited a regular amplitude increase. For the convenience of identification, we extracted the amplitude and area of three characteristic peaks for further analysis.
Fig. 2 Concentration gradient change of the L-hydroxyproline spectrum. a THz absorption spectra of L-hydroxyproline samples at different concentrations measured experimentally. b Absorbance at 0.73 THz (square), 1.13 THz (circle) and 1.78 THz (pentagram) for different concentrations of L-hydroxyproline samples. c The area under the absorption peaks of all L-hydroxyproline samples; error bars have been labelled on each data point.

As shown in Fig. 2b and 2c, linear fittings on the data were performed according to the Beer-Lambert law. The corresponding linear fitting function expressions are:

\[ y_{0.73\text{THz}} = 0.16257x, \quad R^2 = 0.99501 \quad (1) \]

\[ y_{1.13\text{THz}} = 0.17115x, \quad R^2 = 0.99566 \quad (2) \]

\[ y_{1.78\text{THz}} = 0.88148x, \quad R^2 = 0.99768 \quad (3) \]

\[ S_{0.73\text{THz}} = 0.01755x, \quad R^2 = 0.99698 \quad (4) \]

\[ S_{1.13\text{THz}} = 0.03177x, \quad R^2 = 0.99432 \quad (5) \]
\[ S_{1.78\text{THz}} = 0.1566x, R^2 = 0.99597 \]  

\( x \) is the sample concentration, \( y \) is the amplitude \( S \) is the area in the expression, and \( R^2 \) is the correlation coefficient. Eq. (1)-(3) correspond to the peak amplitudes at 0.73, 1.13 and 1.78 THz, and Eq. (4)-(6) correspond to the areas of these three peaks. The corresponding \( R^2 \) values show that the amplitude and area of the three peaks of L-hydroxyproline all have a very good linear relationship with the concentration. Therefore, the concentration of L-hydroxyproline can be effectively calibrated and identified by its THz characteristic peak amplitude and area, which can be used to distinguish different stages of renal fibrosis.

**STEP 2: Mixture interference removal**

After confirming that L-hydroxyproline has a clear THz characteristic peak that changes linearly with concentration, we started the rat test to observe whether this biomarker can be recognized in tissue samples. The unilateral ureteral obstruction (UUO) rat model was used to study interstitial fibrosis (see Methods). A total of 20 male Sprague-Dawley rats were randomly divided into the following four groups: the sham group (sham) represented normal kidneys, the UUO day 3 group (D3) represented early injury, the UUO day 7 group (D7) represented moderate fibrosis, and the UUO day 14 group represented severe fibrosis (D14). The corresponding pathologic images and THz spectra of the four different groups are shown in Fig. 3.

Fig. 3a1-3a4 shows the pathological features of renal tissue in rats. In the sham group, the renal tissue structure was normal. Three days after the UUO operation, the renal tubules were slightly dilated, the renal interstitium was oedematous, the interstitium was widened, and the “back-to-back” characteristics were lost. There were scattered infiltrating inflammatory cells in the tubulointerstitium. Seven days after UUO, some proximal tubules showed vacuolar degeneration, epithelial cells were seen in the renal tubules, the renal tubules at the junction of the medulla and
dermis medulla were obviously expanded, and a large number of inflammatory cells had infiltrated. On the 14th day after UUO, some tubules had disappeared, the collecting duct and distal renal tubule had expanded into cysts, inflammatory cell infiltration and fibroblast proliferation were obvious, and the cortex was thinner. These microscopic images are common evidence of clinical prognosis, but the accuracy of early diagnosis is low. For the early detection of fibrosis, alkaline hydrolysis (AH) or liquid chromatography-mass spectrometry (LC-MS) could be used to quantify the hydroxyproline contents and complete the diagnosis. Although these two methods are expensive and time-consuming, there is no better alternative in clinical practice. For the convenience of comparison, we prepared 5 rats for each stage of the disease. Each UUO kidney homogenate was divided into three separate parts for AH, LC-MS and THz detection.

Fig. 3b shows the THz absorption spectra of rat renal tissue at different stages after UUO operation. It can be clearly seen that the spectral shape of rat kidney tissue had changed compared with that in the spectrum of the biomarker L-hydroxyproline. In addition to the mixture causing other characteristic peaks (such as those at 0.15, 0.41, 1.27, and 1.63 THz), the relative intensity and discrimination of the peaks were changed. Fortunately, the absorption peaks at 0.69 and 1.02 THz still had high amplitude and could be effectively distinguished from the background signal. However, the characteristic peak at 1.82 THz had undergone interference by the absorption lines of other substances in the mixture, making it difficult to distinguish effectively. Therefore, after animal model validation, only two of the three characteristic peaks were effective, and the absorption peak at 1.82 THz was discarded. Other characteristic peaks, such as those at 0.41 and 1.27 THz, showed significant changes, but they cannot be used for qualitative diagnosis and quantitative analysis of diseases because their correlation with the disease cannot be determined. Based on the two characteristic peaks at 0.69 and 1.02 THz, we can see that the overall amplitude of the characteristic peaks increases regularly with the evolution of pathological stage, which indicates that the
quantitative detection of L-hydroxyproline in rat kidney tissue by the THz-TDS system is expected to provide a basis for accurate medical diagnosis.

Fig. 3 Medical and THz test results in a UUO rat model. (a1 - a4) Kidney histologic changes in the UUO rat model. a1 Sham a2 UUO d3 group a3 UUO d7 group a4 UUO d14 group (Masson staining, 200 times magnification). During each stage, five rats were tested. b THz absorption spectra of rat kidneys at different stages of renal fibrosis. c - f Hydroxyproline expression in different groups of UUO rat models by alkaline hydrolysis (c - d) and LC-MS/MS methods (e - f). g - h THz-TDS detection in UUO kidneys by THz intensity g and THz area h.
For quantitative analysis, we calculated the area under the peak of these two absorption peaks of each spectrum; that is, by integrating the spectral area of 0.59-0.84 THz and 0.84-1.14 THz, the corresponding values were used as the judgement criteria of different fibrosis stages. The corresponding results are shown in Fig. 3c & 3e & 3g. Considering the different data units of the three methods, we presented the normalized values and the corresponding error bars to compare the accuracy and sensitivity in disease classification. It can be clearly seen that the measured average values of the AH and LC-MS methods are very close to each other. The difference between the second and first stages is very small, and the third and fourth stages are significantly different. In addition, the AH and LC-MS methods require a multi-step chemical pretreatment [see Methods] and are sensitive to the operator and operation process, so the error bars are large. The THz-TDS method presents much higher values at UUO d3 and d7, and the corresponding error bars are much smaller than those of AH and LC-MS because THz-TDS is a physical spectral detection method that requires no pre-processing, reducing sample loss and maximizing the effective signal. In addition, the non-destructiveness and repeatability of THz-TDS measurements greatly decrease the error rate. To help clarify the standard deviation, these data are polynomially fitted as follows:

\[
\text{LC-MS: } y = 1.22 - 2.08x + 0.99x^2 - 0.12x^3 \quad (7)
\]

\[
\text{AH: } y = 0.25 - 0.41x + 0.17x^2 - 0.01x^3 \quad (8)
\]

\[
\text{THz-TDS: } y = 0.53 - 1.13x + 0.70x^2 - 0.10x^3 \quad (9)
\]

where \(x\) represents the UUO days, and \(y\) represents the signal intensity detected by different methods. Mathematically, the THz fitting curve has the highest slope at low concentrations among all the methods; i.e., the THz method has higher sensitivity for lower-concentration samples. On the other hand, the 0.675% error bars of THz measurements (VS the 11.155% and 11.914% error bars of AH and LC-MS, respectively) obtained from the multiple measurements also indicate its
high repeatability in identifying the presence and concentration of the biomarker L-hydroxyproline in real tissues.

Furthermore, to quantitatively compare the differences between these three test methods of AH, LC-MS, and THz-TDS, we calculated the standard deviation and root mean square error for the four stages of the UUO rat model, as presented in Table 5. The differences in magnitude ($S_{THz}: S_{AH}: S_{LC-MS} = 10^{-2}: 10^{-1}: 10^{-1}$, $RMSE_{THz}: RMSE_{AH}: RMSE_{LC-MS} = 10^{-5}: 10^{-2}: 10^{-2}$) directly prove that the THz method has a higher accuracy and sensitivity than AH and LC-MS. These results are highly useful in the early identification of the biomarker L-hydroxyproline with greater confidence.

**Table 5.** The standard deviation and root mean square error for the four stages of the UUO rat model.

| UUO rat kidney samples | Standard deviation (S) | Root mean square error (RMSE) |
|------------------------|------------------------|-----------------------------|
|                        | AH         | LC-MS    | THz         | AH      | LC-MS    | THz      |
| sham                   | 1.01E-01  | 1.38E-01 | 3.38E-02   | 1.06E-02| 1.62E-02| 8.26E-05 |
| UUO d3                 | 2.37E-01  | 1.54E-01 | 3.20E-02   | 5.14E-02| 1.86E-02| 6.39E-05 |
| UUO d7                 | 9.79E-02  | 2.93E-01 | 2.86E-02   | 4.97E-03| 2.80E-02| 3.97E-05 |
| UUO d14                | 3.45E-01  | 2.60E-01 | 3.10E-02   | 3.03E-02| 1.44E-02| 4.31E-05 |
| Average                | 1.95E-01  | 2.11E-01 | 3.14E-02   | 2.43E-02| 1.93E-02| 5.73E-05 |

We analysed the results of the LC-MS, AH and THz tests by using the one-way analysis of variance (ANOVA) method, as shown in Fig. 3d&3f&3h. It can be clearly seen that for both the LC-MS and AH methods, the P values were all greater than 0.05 ($P_{AH}=0.6293$, $P_{MS}=0.7286$) in the second stage (Fig. 3d&1f), which indicated that the early stage of fibrosis could not be effectively distinguished. By comparison, THz detection showed good differentiation (Fig. 3h). For the third and fourth stages, all three methods effectively identified fibrosis, but the THz method had a smaller
error and higher discrimination. Therefore, the accuracy of early diagnosis for the THz method is much higher than that of the other two conventional methods.

**STEP 3: Individual difference removal**

After confirming the feasibility of tissue detection in a rat model, we carried out an experiment with real human kidney tissue. Because samples of human renal fibrosis tissue are very rare and the total amount of each sample is small, we first adopted the test mode of non-destructive detection with the THz method and then evaluated the degree of fibrosis by histopathology and the AH method (the amount of single tissue was not enough to support both the AH and LC-MS methods, so we chose only the conventional AH method). According to the area of renal fibrosis, the patients were divided into a normal group and a fibrosis group. The general information on the two groups is shown in Table 6.

**Table 6. Clinical characteristics of 14 patients.**

| Groups      | Sex (M:F) | Age (yr)     | eGFR (ml/min) | Fibrotic area (%) |
|-------------|-----------|--------------|---------------|-------------------|
| Normal      | 4:0       | 50.00±9.41   | 66.75±12.55   | 4.00±0.41         |
| fibrosis    | 6:4       | 57.00±3.25   | 63.80±28.97   | 30.40±8.50        |
Fig. 4 Medical and THz test results of human kidney tissues. a Normal tissue image. b Fibrosis tissue image. c THz absorption spectra of 14 samples of human kidneys. Lines with different colours represent different human kidney samples, and the corresponding error bars are labelled. The red dotted box shows the THz spectra of the biomarker L-hydroxyproline. The numbers 1-14 represent the 14 human renal fibrosis samples. d-e The difference between human normal and fibrotic tissues by the AH and THz-TDS methods. All data are normalized to their maximum.

According to Masson staining, 14 renal tissues were divided into a normal group (n = 4) and a fibrosis group (n = 10). The average age of the normal group was 50.00 ± 9.41 years (mean eGFR
66.75 ± 6.28 mL/min), and the fibrotic area was 4.00 ± 0.82%; the average age of the fibrosis group was 57.00 ± 3.25 years, the average eGFR was 65.36 ± 8.30 mL/min, and the fibrotic area was 30.40 ± 8.50%. Fig. 4a shows a pathological image of normal human kidney tissue. The glomerular capillary loop is well opened, and the renal tubules are back-to-back. No obvious tubular atrophy, interstitial fibrosis or inflammatory cell infiltration was found. Fig. 4b presents a pathological image of a human fibrotic kidney with obvious glomerulosclerosis, tubular atrophy with interstitial fibrosis and inflammatory cell infiltration.

The THz absorption spectra of human samples are shown in Fig. 4c. The spectra of human kidney tissue changed again compared to those of the rat model. The central frequency of the first characteristic peak at 0.69 THz in the rat sample redshifted slightly to 0.64 THz, and the central frequency of the characteristic peak at 1.02 THz did not change; the biomarker-unrelated peaks at 0.15, 0.41, 1.27, and 1.63 THz in Fig. 3b no longer exhibit obvious or regular changes in Fig. 4c. We speculate that this is because the rats in the UUO model were fed uniformly and injected quantitatively. However, the individual differences among human bodies (the proportion and content of each component varies with individual age, sex, physique, nutrition, exercise and other factors) will change the centre frequency of the overlapping spectrum, which causes the spectrum to no longer have obvious regular changes. However, the content of hydroxyproline, a common characteristic of renal fibrosis patients, increased significantly, making its characteristic peak still more significant and able to be effectively identified.

As in UUO, we integrated the area under the peak of the two characteristic peaks at 0.64 and 1.02 THz, corresponding to the frequency range of 0.50-0.86 THz and 0.86-1.19 THz, respectively, as shown in the red box in Fig. 4c. The relevant data and AH test results were divided into two groups, normal and pathological, as shown in Fig. 4d and 4e. The results showed that the content of hydroxyproline and the area under the peaks by THz-TDS in renal fibrotic and normal tissues
were significantly increased, and there was a significant difference between the two groups by THz intensity and THz peak area assessment. Considering these results and the rapidity, simple operation and losslessness of the THz method, we conclude that the overall effect of the THz method is much better than that of the AH method.

Discussion

Now, we can deduce that these series of experiments directly prove the high sensitivity, accuracy and early recognition rate of THz methods for renal fibrosis. This sensitivity to different stages of renal fibrosis can be directly used for the dynamic monitoring of chronic kidney disease. This good performance may be due to four factors: (1) the high directionality of the THz beam yields a high collection efficiency; (2) the transmission-type detection results in a strong absorption of THz waves by each biomarker molecule in the sample; (3) the detection process for the THz method has only one step—inserting the sample into the system—which is quick and has no mass loss or denaturation; and (4) the non-destructive detection of the THz method allows repeated measurements so that we can obtain error bars to quantify the reliability of the result (a single THz measurement takes only a few seconds). Finally, the corresponding spectrum contains all the useful information. In contrast, the AH and LC-MS methods both use multiple and complex chemical reactions followed by spectral analyses. The more complex the workflows are, the more operation steps there are, which inevitably results in a reduced amount of sample and thereby a decreased signal.

So far, we have completed the three-step one-way model of the THz method: first, we screened the biomarkers of diseases to confirm whether the THz characteristic peaks exist in the effective detection range; second, by observing the interference degree of the mixture on the characteristic peaks of the biomarker by rat tissues, we confirmed the effective and recognizable characteristic
peaks; and third, we excluded the influence of individual differences in human tissues and confirmed the most effective and recognizable characteristic peaks. Finally, the THz characteristic peak can be used effectively, allowing accurate comparison and evaluation. This one-way process gradually eliminates the interference of uncertain factors and other non-disease-related substances and establishes a standardized process for the rapid and noninvasive diagnosis of clinical diseases by the THz method.

Conclusion

In summary, we provide a “THz three-step one-way” model for disease detection, which details the process of THz dynamic monitoring of disease evolution and the method of eliminating interference. Compared with AH and LC-MS, THz-TDS can improve the accuracy, sensitivity and detection speed of diagnosis. Its high sensitivity, high accuracy and high speed highlight its potential in the early diagnosis, staging evaluation and disease monitoring of biological diseases. In the future, this kind of dynamic monitoring is expected to achieve real-time imaging during operation, which can greatly improve the accuracy of surgery.

Acknowledgements

The authors are grateful to Professor Bo Song for fruitful discussions.

Author contributions

YP, YZ, JH and CY conceived the study and designed the experiments. JL and ZY performed the fibrosis experiments. LW, XW and XZ designed and performed theoretical simulations. JH and CY provided all samples, provided expertise for fibrosis progression, and performed the AH and LC-MS experiments in the hospital. QH, MG and SZ provided useful advice. YP and JH wrote the manuscript.
Funding

This work is financially supported by NSFC (61922059, 81961138014, 61805140, 81873609, 61771314) and the Terahertz Science and Technology Frontier Project (6198802).

Availability of data and materials

The calculation and experiment data that support the works of this study are available from the corresponding authors on reasonable request.

Competing interests

The authors declare no competing interests.

Authors' information

1Terahertz Technology Innovation Research Institute, Shanghai Key Lab of Modern Optical System, and Shanghai Cooperation Innovation Centre of Terahertz Spectroscopy and Imaging Technology, University of Shanghai for Science and Technology, Shanghai 200093, P. R. China.

2Department of Nephrology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.

3Department of Electrical Engineering and Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

4Laboratory of Artificial-Intelligence Nanophotonics, University of Shanghai for Science and Technology, Shanghai 200093, P. R. China.

5The Institute of Optics, University of Rochester, Rochester, New York 14627, USA.
References

1. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM, Inflammatory Cortical Demyelination in Early Multiple Sclerosis. N. Engl. J. Med. 2011, 365:2188-97.

2. Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A, RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut 2019, 68:317632.

3. Balázs M, Koroknai V, Szász I, Ecsedi S, "Detection of CCND1 Locus Amplification by Fluorescence In Situ Hybridization" in The Retinoblastoma Protein, P. G. Santiago-Cardona, Ed. (Springer New York, New York, NY,), 2018:85-100.

4. Worlikar T, Mendiratta-Lala M, Vlaisavljevich E, Hubbard R, Shi J, Hall TL, Cho CS, Lee FT, Greve J, Xu Z, Effects of Histotripsy on Local Tumor Progression in vivo Orthotopic Rodent Liver Tumor Model. BME Frontiers 2020:9830304.

5. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau K W, Burton J, Quail MA, Suerdlow H, Churcher C, Natrajan R, Siewerts AM, Martens JWM, Silver DP, Langeröd A, Russnes HEG, Foekens A, Reis-Filho JS, Veer L van ’t, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR, Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 2009,462:1005-10.

6. Philip J, Potts AT, Ellis, Peter, Kregsamer, Christina, Streli, X-ray fluorescence spectrometry. J. Anal. At. Spectrom., 1999.

7. Höhne J, Hohenberger C, Proescholdt M, Riemenschneider MJ, Wendl C, Brawanski A, Schebesch KM, Fluorescein sodium-guided resection of cerebral metastases—an update. Acta Neurochir. 2017, 159:363-7.

8. Stummer W, Tonn JC, Goetz C, Ullrich W, Stepp H, Bink A, Pietsch T, Pichlmeier U, 5-Aminolevulinic Acid-derived Tumor Fluorescence: The Diagnostic Accuracy of Visible Fluorescence Qualities as Corroborated by Spectrometry and Histology and Postoperative Imaging. Neurosurgery, 2013,74, 310-20.

9. Ishizawa T, Fukushima N, Shibahara J, Masuda K, Tamura S, Aoki T, Hasegawa K, Beck Y, Fukayama M, Kokudo N, Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer, 2009, 115, 2491-504.

10. Zhu Y, Zheng W, WangW. et al. Raman tensor of layered black phosphorus. PhotoniX, 2020 ,1:17.

11. You AYF, Bergholt MS, St-Pierre JP, Kit-Anan W, Pence II, Chester AH, Yacoub MH, Bertazzo S, Stevens MM, Raman spectroscopy imaging reveals interplay between atherosclerosis and medial calcification in the human aorta. Sci. Adv. 2017, 3: e1701156.
12. Peng Y, Shi C, Wu X, Zhu Y, Zhuang S, Terahertz Imaging and Spectroscopy in Cancer Diagnostics: A Technical Review. BME Frontiers 2020: 2547609.

13. Peng Y, Shi C, Zhu Y, Gu M, Zhuang S, Terahertz spectroscopy in biomedical field: a review on signal-to-noise ratio improvement. PhotoniX, 2020, 1.

14. Ge H, Jiang Y, Lian F, Zhang Y, Xia S, Quantitative determination of aflatoxin B1 concentration in acetonitrile by chemometric methods using terahertz spectroscopy. Food Chem. 2016, 209: 286-92.

15. Wang Z, Wu J, Yang W, Bera AK, Kamenskyi D, Islam ATMN, Xu S, Law JM, Lake B, Wu C, Loidl A, Experimental observation of Bethe strings. Nature, 2018, 554:219-23.

16. Chanana A, Liu X, Zhang C, Vardeny ZV, Nahata A, Ultrafast frequency-agile terahertz devices using methylammonium lead halide perovskites. Sci. Adv. 2018, 4: eaar7353.

17. Lu S, Zhang X, Zhang Z, Yang Y, Xiang Y, Quantitative measurements of binary amino acids mixtures in yellow foxtail millet by terahertz time domain spectroscopy. Food Chem. 2016, 211:494-501.

18. Peng Y, Shi C, Xu M, Kou T, Wu X, Song B, Ma H, Guo S, Liu L, Zhu Y, Qualitative and Quantitative Identification of Components in Mixture by Terahertz Spectroscopy. IEEE Trans. Terahertz Sci. Technol. 2018, 8:696-701.

19. Wu X, Dai Y, Wang L, Peng Y, Lu L, Zhu Y, Shi Y, Zhuang S, Diagnosis of methylglyoxal in blood by using far-infrared spectroscopy and o-phenylenediamine derivation. Biomed. Opt. Express, 2020, 11:963-70.

20. Stantchev RI, Sun B, Hornett SM, Hobson PA, Gibson GM, Padgett MJ, Hendry E, Noninvasive, near-field terahertz imaging of hidden objects using a single-pixel detector. Sci. Adv. 2016, 2: e1600190.

21. Lee SH, Lee D, Choi MH, Son JH, Seo M, Highly Sensitive and Selective Detection of Steroid Hormones Using Terahertz Molecule-Specific Sensors. Anal. Chem. 2019, 91, 6844-9.

22. Elgabarty H, Kampfrath T, Bonthuis DJ, Balos V, Kaliannan NK, Loche P, Netz RR, Wolf M, Kühne TD, Sajadi M, Energy transfer within the hydrogen bonding network of water following resonant terahertz excitation. Sci. Adv. 2020, 6: eaay7074.

23. Haddad J El, Miollis F de, Sleiman J Bou, Canioni L, Mounaix P, Bousquet B, Chemometrics Applied to Quantitative Analysis of Ternary Mixtures by Terahertz Spectroscopy. Anal. Chem. 2014, 86: 4927-33.

24. Wu X, Wang L, Peng Y, Wu F, Cao J, Chen X, Wu W, Yang H, Xing M, Zhu Y, Shi Y, Zhuang S, Quantitative analysis of direct oral anticoagulant rivaroxaban by terahertz spectroscopy. Analyst, 2020, 145: 3909-15.

25. Du SQ, Li H, Xie L, Chen L, Peng Y, Zhu YM, Li H, Dong P, Wang JT, Vibrational frequencies of anti-diabetic drug studied by terahertz time-domain spectroscopy. Appl. Phys. Lett. 2012, 100: 143702.
26. Sommer S, Koch M, Adams A, Terahertz Time-Domain Spectroscopy of Plasticized Poly(vinyl chloride). Anal. Chem. 2018, 90: 2409-13.

27. Gu H, Shi C, Wu X, Peng Y, Molecular methylation detection based on terahertz metamaterial technology. Analyst, 2020, 145: 6705-12.

28. Peng Y, Yuan X, Zou X, Chen W, Huang H, Zhao H, Song B, Chen L, Zhu Y, Terahertz identification and quantification of neurotransmitter and neurotrophy mixture. Biomed. Opt. Express 7, 2016, 7: 4472-9.

29. Li T, Ma H, Peng Y, Chen X, Zhu Z, Wu X, Kou T, Song B, Guo S, Liu L, Zhu Y, Gaussian numerical analysis and terahertz spectroscopic measurement of homocysteine. Biomed. Opt. Express 2019, 8: 5467-76.

30. Ajito K, Ueno Y, Kim JY, Sumikama T, Capturing the Freeze-Drying Dynamics of NaCl Nanoparticles Using THz Spectroscopy. J. Am. Chem. Soc. 2018, 140, 13793-7.

31. Zhou D, Liu Y, Understanding the mechanisms of kidney fibrosis. Nat. Rev. Nephrol. 2016, 12: 68-70.

32. Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, Nagaraja H, Indrakanti D, Rovin BH, Histologic versus clinical remission in proliferative lupus nephritis. Nephrol., Dial., Transplant. 2017. 32: 1338-44.

33. Mengel M, Chapman JR, Cosio FG, Cavaille-Coll MW, Haller H, Halloran PF, Kirk AD, Mihatsch MJ, Nankivell BJ, Racusen LC, Roberts IS, Rush DN, Schwarz A, Seron D, Stegall MD, Colvin RB, Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am. J. Transplant. 2007, 7: 512-7.

34. Zhuo L, Wang H, Chen D, Lu H, Zou G, Li W, Alternative renal biopsies: past and present. Int. Urol. Nephrol. 2018, 50: 475-9.

35. Torres HR, Queirós S, Morais P, Oliveira B, Fonseca JC, Vilaça JL, Kidney segmentation in ultrasound, magnetic resonance and computed tomography images: A systematic review. Comput. Meth. Prog. Bio. 2018, 157: 49-67.

36. Zhang X, Li X, Zhou W, Liu X, Huang J, Zhang Y, Lindholm B, Yu C, Serum Lysyl Oxidase Is a Potential Diagnostic Biomarker for Kidney Fibrosis. Am. J. Nephrol. 2020, 51: 907-18.

37. Nakhjavani M, Etemadi J, Pourlak T, Mirhosaini Z, Zununi Vahed S, Abediazar S, Plasma levels of miR-21, miR-150, miR-423 in patients with lupus nephritis. Iran. J. Kidney. Dis. 2019, 13: 198-206.

38. Frisch MJ, Trucks G, Schlegel HB, Scuseria GE, Robb MA, Cheeseman J, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg J, Hada M, Fox D, Gaussian 09 Revision A.1. Gaussian Inc. 2009.

39. Joseph J, Jemmis ED, Red-, Blue-, or No-Shift in Hydrogen Bonds: A Unified Explanation. J. Am. Chem. Soc. 2007, 129: 4620-32.
Shen YC, Upadhya PC, Linfield EH, Davies AG. Temperature-dependent low-frequency vibrational spectra of purine and adenine. Appl. Phys. Lett. 2003, 82: 2350-2.